Travere Therapeutics, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report; the supplied text does not provide a complete set of Q4-only financial results. The company is a rare-disease biopharmaceutical business with marketed products and clinical-stage programs. FDA approval of FILSPARI occurred on February 17, 2023, after the reporting period.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Total revenue | $212.0 million | $227.5 million |
| Net product sales | $200.5 million | $210.8 million |
| Operating loss | $266.6 million | $161.8 million |
| Net loss | $278.5 million | $180.1 million |
| Net loss per share, basic and diluted | $4.37 | $3.01 |
| Cash used in operating activities | $186.3 million | $14.8 million |
| Cash and cash equivalents at year-end | $61.7 million | $165.8 million |
| Marketable debt securities at year-end | $388.6 million | $387.1 million |
| Net working capital / ratio | $344.3 million / 3.42 | $458.7 million / 4.70 |
| Convertible debt, carrying value | $375.5 million | $226.6 million |
Revenue declined about 6.8%, while net loss widened about 54.6%. Research and development expense rose to $235.8 million from $210.3 million; selling, general and administrative expense rose to $220.2 million from $149.9 million, reflecting pipeline investment, workforce growth and FILSPARI launch preparations. The filing does not state a single company-wide gross margin. Cash and short-term investments totaled approximately $450.2 million at year-end.
Net product sales fell as tiopronin sales declined to $98.0 million from $115.1 million, primarily due to generic competition; bile-acid product sales increased to $102.6 million from $95.7 million. License and collaboration revenue was $11.5 million, versus $16.7 million in 2021, which included $12.0 million recognized for the CSL Vifor license.
Financing cash flow included issuance of $316.3 million principal amount of 2029 convertible notes and repurchase of $207.1 million principal amount of 2025 notes. The company reported $68.9 million principal remaining on the 2025 notes and $316.3 million on the 2029 notes. Operating cash outflow increased substantially, and the company reported a $7.6 million loss on extinguishment of debt.
Business developments, outlook and risks
- FILSPARI / IgAN: The FDA granted accelerated approval in February 2023 to reduce proteinuria in adults with primary IgAN at risk of rapid progression, generally UPCR of at least 1.5 g/g. The filing says kidney-function benefit has not yet been established; continued approval may depend on confirmatory results. Management expected launch availability the week of February 27, 2023, and PROTECT two-year topline results in Q4 2023. The label includes a REMS and boxed warnings relating to liver injury and embryo-fetal toxicity.
- Other pipeline: DUPLEX confirmatory results for FSGS were expected in Q2 2023; the FDA had said the submitted data did not support an accelerated-approval filing, while traditional approval remained possible after study completion. Additional pegtibatinase Phase 1/2 data were expected mid-2023, with a potential Phase 3 start in H2 2023 subject to FDA feedback. The company expected to complete the Chenodal CTX Phase 3 study during 2023, pending supportive results.
- Management outlook: Management said available cash and short-term investments, together with anticipated operating cash generation, should fund the expected level of operations beyond the next 12 months. It also expected near-term operating losses and rising expenses for commercialization and R&D; future funding needs depend on results, spending, revenue and capital-market access.
- Commitments and contingent items: The company had a $36.3 million commitment to purchase FILSPARI active pharmaceutical ingredient for delivery in 2023. Accelerated approval triggered a $23.0 million Ligand/BMS milestone payable in Q1 2023, plus future sparsentan royalties of 15%–17% of net sales. The French distributor was notified of a potential recoupment relating to historical Kolbam sales; the possible liability was not estimable. The filing reports no claim or litigation expected to have a material adverse effect, but outcomes remain uncertain.
- Financial reporting control: Management and the auditor identified a material weakness in controls over accounting for a pre-launch inventory contract and the timing of R&D expense recognition. Disclosure controls were judged ineffective, and the auditor issued an adverse opinion on internal control over financial reporting. A $7.7 million out-of-period adjustment reduced R&D expense and accrued expenses; management said it was not material and no restatement was required. Remediation was underway.
- Other principal risks: FILSPARI launch execution, payer coverage and pricing, confirmatory clinical results, generic competition affecting legacy products, reliance on sole-source manufacturers and distributors, debt service and financing access, and the possibility of adverse safety or regulatory developments.
Investor facts to verify
- Whether FILSPARI launch uptake, access, reimbursement and safety monitoring support management’s commercial expectations.
- Final PROTECT confirmatory results and their implications for traditional approval and any broader IgAN label; final DUPLEX results and the FSGS regulatory path.
- Cash burn, cash and investment balances, financing needs, and capacity to meet debt, royalty and manufacturing commitments.
- Revenue trends and generic impact for Thiola and other legacy products, including the status of potential Thiola EC patent challenges.
- Progress and testing of the remediation plan for the material weakness, and any subsequent-period financial reporting changes.
- Resolution or update on the French Kolbam reimbursement matter and any other material litigation or regulatory inquiries.